MedTrace Logo

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

NCT04828057 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-10-31

No results posted yet for this study

Summary

The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment from initiation, in patients with open angle glaucoma (OAG) or ocular hypertension (OHT), who do not respond sufficiently to initial topical treatment, in routine clinical practice.

Conditions

  • Ocular Surface Disease
  • Primary Open Angle Glaucoma

Interventions

DRUG

Tafluprost, timolol maleate

Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.

Sponsors & Collaborators

  • Santen Pharmaceutical (Taiwan) Co., LTD

    lead INDUSTRY

Principal Investigators

  • Wei-wen Su · Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-08-24
Completion
2022-08-24

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04828057 on ClinicalTrials.gov